Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to healthcare.

The TM program described comprises a population that faces many barriers to effective HCV treatment – genotype 3 (25.9% vs. 16.4%),  Indigenous (7.0% vs. 2.2%)  history of injection drug use (70.1% vs. 54.9%) and incarceration (46.5% vs 35.5%).

The study found TM patients initiated HCV therapy and achieved High SVR rates comparable to those obtained using traditional models of care.

Read the complete report here: https://goo.gl/AAozhc

Source: http://www.annalsofhepatology.com/vista?accion=viewArticle&idart=1530